TY - JOUR
T1 - Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation
T2 - A retrospective study based on the time of HLA typing and donor availability
AU - Sarina, Barbara
AU - Castagna, Luca
AU - Farina, Lucia
AU - Patriarca, Francesca
AU - Benedetti, Fabio
AU - Carella, Angelo M.
AU - Falda, Michele
AU - Guidi, Stefano
AU - Ciceri, Fabio
AU - Bonini, Alessandro
AU - Ferrari, Samantha
AU - Malagola, Michele
AU - Morello, Enrico
AU - Milone, Giuseppe
AU - Bruno, Benedetto
AU - Mordini, Nicola
AU - Viviani, Simonetta
AU - Levis, Alessandro
AU - Giordano, Laura
AU - Santoro, Armando
AU - Corradini, Paolo
PY - 2010/5/6
Y1 - 2010/5/6
N2 - Hodgkin lymphoma relapsing after autologous transplantation (autoSCT) has a dismal outcome. Allogeneic transplantation (alloSCT) using reduced intensity conditioning (RIC) is a salvage option, but its effectiveness is still unclear. To evaluate the role of RIC alloSCT, we designed a retrospective study based on the commitment of attending physicians to perform a salvage alloSCT; thus, only Hodgkin lymphoma patients having human leukocyte antigen-typing immediately after the failed autoSCT were included. Of 185 patients, 122 found an identical sibling (55%), a matched unrelated (32%) or a haploidentical sibling (13%) donor; 63 patients did not find any donor. Clinical features of both groups did not differ. Two-year progression-free (PFS) and overall survival (OS) were better in the donor group (39.3% vs 14.2%, and 66% vs 42%, respectively, P <.001) with a median follow-up of 48 months. In multivariable analysis, having a donor was significant for better PFS and OS (P <.001). Patients allografted in complete remission showed a better PFS and OS. This is the largest study comparing RIC alloSCT versus conventional treatment after a failed auto-SCT, indicating a survival benefit for patients having a donor.
AB - Hodgkin lymphoma relapsing after autologous transplantation (autoSCT) has a dismal outcome. Allogeneic transplantation (alloSCT) using reduced intensity conditioning (RIC) is a salvage option, but its effectiveness is still unclear. To evaluate the role of RIC alloSCT, we designed a retrospective study based on the commitment of attending physicians to perform a salvage alloSCT; thus, only Hodgkin lymphoma patients having human leukocyte antigen-typing immediately after the failed autoSCT were included. Of 185 patients, 122 found an identical sibling (55%), a matched unrelated (32%) or a haploidentical sibling (13%) donor; 63 patients did not find any donor. Clinical features of both groups did not differ. Two-year progression-free (PFS) and overall survival (OS) were better in the donor group (39.3% vs 14.2%, and 66% vs 42%, respectively, P <.001) with a median follow-up of 48 months. In multivariable analysis, having a donor was significant for better PFS and OS (P <.001). Patients allografted in complete remission showed a better PFS and OS. This is the largest study comparing RIC alloSCT versus conventional treatment after a failed auto-SCT, indicating a survival benefit for patients having a donor.
UR - http://www.scopus.com/inward/record.url?scp=77952574651&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77952574651&partnerID=8YFLogxK
U2 - 10.1182/blood-2009-12-253856
DO - 10.1182/blood-2009-12-253856
M3 - Article
C2 - 20220116
AN - SCOPUS:77952574651
VL - 115
SP - 3671
EP - 3677
JO - Blood
JF - Blood
SN - 0006-4971
IS - 18
ER -